James C. Greenwood

New reports indicate that drug prices are slowing compared to other healthcare costs.

Policies for patient access to life-saving therapies must keep pace with biomedical innovation.

Protecting intellectual property rights is vital to biopharmaceutical innovation.

Sound policies are needed to govern the substitution of interchangeable biologics.

Ties between the biotechnology industry and university research are crucial.

BIO's president and CEO provides insight leading up to the 2011 convention.

This year's BIO International Convention will be occurring against a backdrop of profound change in our industry.

A key to bolstering FDA and its mission is securing balanced and consistent funding.